← Back to patent-cliff list
Capsaicin (Propella Therapeutics)
Tier C — Watch / tradeCapsaicin (Propella Therapeutics)
Propella Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TRPV1
Indications (approved)：Osteoarthritis, Pain, Knee arthritis, Arthralgia
Regional status
US
No progress
2018-05-14
EU
-
China
Phase II
2025-09-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Capsaicin (Propella Therapeutics)?
Approved indications include: Osteoarthritis, Pain, Knee arthritis, Arthralgia.
When does the Capsaicin (Propella Therapeutics) patent expire?
No public expiry year is available for Capsaicin (Propella Therapeutics) yet; this page updates once verified.
How do I get a quote for Capsaicin (Propella Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08